✦ LIBER ✦

0142 Feasibility study of fluorouracil/epirubicin/cyclophosphamide (FEC75) followed by docetaxel (DOC) as adjuvant chemotherapy in Japanese patients with node positive breast cancer

✍ Scribed by Y. Rai; M. Tanaka; M. Mitsuyama; T. Uga; S. Tanaka; K. Nanba; H. Furusawa; K. Murata; R. Nishimura; T. Oikawa; Y. Kamada; S. Maeda; J. Maeda; S. Honjyo; H. Iwase; Y. Yamamoto; K. Masuno; K. Shibuta; Y. Kai; H. Taniguchi; T. Yahara; G. Yokoyama; Y. Yoshinaga; S. Umeda; K. Hisamatsu; K. Tamura

Book ID: 114316279
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 54 KB
Volume: 18
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(09)70173-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P278 Feasibility study of adjuvant fluor

P278 Feasibility study of adjuvant fluorouracil/epirubicin/cyclophosphamide (FEC 100) followed by triweekly docetaxel (D) plus trastuzumab (H) in HER2/neu positive early breast cancer

✍ M. Tanaka; K. Anan; S. Umeda; M. Yamaguchi; H. Sasaki; Y. Rai; S. Ohno; U. Toh; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 55 KB

FEC versus sequential docetaxel followed

FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)

✍ Aristides Polyzos; Nikolaos Malamos; Ioannis Boukovinas; Adamos Adamou; Nikolaos 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 296 KB

Randomized phase III trial of adjuvant e

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

✍ Dino Amadori; Rosella Silvestrini; Mario De Lena; Francesco Boccardo; Andrea Roc 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 485 KB

A phase III adjuvant randomised trial of

A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)

✍ Delbaldo, C.; Serin, D.; Mousseau, M.; Greget, S.; Audhuy, B.; Priou, F.; Berdah 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 761 KB

Long-term Cardiac Follow-up in Relapse-F

Long-term Cardiac Follow-up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, as Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group

✍ Shapiro, C.L. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 56 KB

A Phase II Feasibility Trial of Dose-Den

A Phase II Feasibility Trial of Dose-Dense Docetaxel Followed by Doxorubicin/Cyclophosphamide as Adjuvant or Neoadjuvant Treatment for Women with Node-Positive or High-Risk Node-Negative Breast Cancer

✍ Denise A. Yardley; Howard A. Burris III; Cindy P. Farley; John H. Barton; Nancy 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 109 KB